Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
SB 9200: Successfully completed a preliminary, IND-enabling, dose-ranging finding study in non-human primates.

Spring Bank Pharmaceuticals successfully completed a preliminary, IND-enabling, dose-ranging finding study in non-human primates. SB 9200 is well tolerated up to 500 mg/kg/day for four days of once-daily oral dosing.  A 14 day IND-enabling dose ranging toxicology and toxicokinetics study of SB 9200 will be initiated in early September.